Executive Interviews

  1. The Immigrant Approach To Biotech Formation 8/1/2023

    Flagship Pioneering General Partner Avak Kahvejian, Ph.D., says successfully ideating new biotech companies — which Flagship has done in spades — requires the curiosity, skepticism, and paranoia of a new inhabitant in foreign land. Oh, and a little bit of machine learning won’t hurt.

  2. Novo Nordisk Returns To Growth, With Growing Pains 8/1/2023

    Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.

  3. I-MAK's Quest To Trim The Biopharmaceutical Patent Thicket 7/3/2023

    I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.

  4. Civica Takes On Insulin Market, Opens Manufacturing Facility 7/3/2023

    With a new manufacturing plant opening in Virgina, Civica is poised to move into new product areas, including affordable insulin.

  5. From Biggest Pharma To Rare Disease Start-Up 6/1/2023

    Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech. 

  6. Leading Aulos Bioscience's “Triumvirate” Model 6/1/2023

    Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.

  7. The Skin Is The Game: New Ways To Play In Dermatology 5/1/2023

    As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.

  8. Fortress Biotech's Network Flex Business Model 5/1/2023

    Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.

  9. Hitting The Ground Running In Oncology 4/3/2023

    David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.

  10. U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin 4/3/2023

    Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.